Compare Stocks

Date Range: 

 Jaguar HealthChiasmaAVEO PharmaceuticalsNovanGenprex
SymbolNASDAQ:JAGXNASDAQ:CHMANASDAQ:AVEONASDAQ:NOVNNASDAQ:GNPX
Price Information
Current Price$1.31$4.03$6.43$1.22$3.42
52 Week RangeN/AHoldBuyBuyBuy
MarketRank™
Overall Score0.91.61.21.61.2
Analysis Score0.03.23.53.53.5
Community Score4.42.42.62.22.4
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.01.70.0
Earnings & Valuation Score0.00.60.00.60.0
Analyst Ratings
Consensus RecommendationN/ABuyBuyBuyBuy
Consensus Price TargetN/A$11.67$17.80$2.50$6.00
% Upside from Price TargetN/A189.50% upside176.83% upside104.92% upside75.44% upside
Trade Information
Market Cap$170.34 million$233.11 million$220.94 million$185.02 million$161.99 million
Beta1.831.591.40.01-0.57
Average Volume28,726,3612,895,9212,028,00513,432,7441,345,445
Sales & Book Value
Annual Revenue$5.78 millionN/A$28.80 million$4.90 millionN/A
Price / Sales29.47N/A7.6737.76N/A
CashflowN/AN/A$0.46 per shareN/AN/A
Price / CashN/AN/A14.08N/AN/A
Book Value$0.16 per share$2.04 per share$0.92 per share($0.89) per share$0.15 per share
Price / Book8.19N/A6.99-1.37N/A
Profitability
Net Income$-38,540,000.00$-36,320,000.00$9.39 million$-30,640,000.00$-10,650,000.00
EPS($6.89)($1.06)$0.61($0.80)($0.67)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-372.81%N/A-483.99%-379.35%N/A
Return on Equity (ROE)-659.73%-83.82%-103.66%N/A-81.49%
Return on Assets (ROA)-76.08%-56.55%-48.01%-43.81%-79.54%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.26%N/A0.34%0.11%N/A
Current Ratio0.42%9.44%4.29%5.56%60.40%
Quick Ratio0.33%8.95%4.29%5.56%58.58%
Ownership Information
Institutional Ownership Percentage1.42%71.29%33.70%6.23%12.50%
Insider Ownership Percentage3.24%5.50%4.50%3.00%13.05%
Miscellaneous
Employees2985492312
Shares Outstanding130.03 million57.84 million34.36 million151.65 million47.36 million
Next Earnings Date5/21/2021 (Estimated)8/9/2021 (Estimated)5/10/2021 (Confirmed)5/19/2021 (Estimated)5/13/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer - Yahoo FinanceGenprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer - Yahoo Finance
finance.yahoo.com - May 7 at 8:47 AM
Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer - Business WireGenprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer - Business Wire
businesswire.com - May 7 at 8:47 AM
Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer - Yahoo FinanceGenprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer - Yahoo Finance
finance.yahoo.com - May 7 at 3:47 AM
NA Proactive news snapshot: Esports Entertainment Group, BioHarvest Sciences, ESE Entertainment, Genprex UPDATE … - Proactive Investors USANA Proactive news snapshot: Esports Entertainment Group, BioHarvest Sciences, ESE Entertainment, Genprex UPDATE … - Proactive Investors USA
proactiveinvestors.com - May 6 at 5:47 PM
Proactive news headlines including Binovi Technologies, Genprex, Esports Entertainment Group and Golden Minerals Company - Yahoo FinanceProactive news headlines including Binovi Technologies, Genprex, Esports Entertainment Group and Golden Minerals Company - Yahoo Finance
finance.yahoo.com - May 6 at 5:47 PM
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Expansion of World-Class IP Portfolio - StreetInsider.comBioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Expansion of World-Class IP Portfolio - StreetInsider.com
streetinsider.com - May 6 at 5:47 PM
Is Genprex Inc (GNPX) a Stock to Watch After Losing -11.00% This Week? - InvestorsObserverIs Genprex Inc (GNPX) a Stock to Watch After Losing -11.00% This Week? - InvestorsObserver
investorsobserver.com - May 6 at 12:46 PM
Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer - WV NewsGenprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer - WV News
wvnews.com - May 6 at 12:46 PM
Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung CancerGenprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer
finance.yahoo.com - May 6 at 12:46 PM
Altium Capital Management LP B - GuruFocus.comAltium Capital Management LP B - GuruFocus.com
gurufocus.com - May 6 at 7:45 AM
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial - StreetInsider.comBioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial - StreetInsider.com
streetinsider.com - May 6 at 2:45 AM
Proactive news headlines including Mountain Valley MD Holdings, Snowline Gold, Altamira Gold Corp, Heritage Cannabis Holdings and Planet 13 Holdings - StreetInsider.comProactive news headlines including Mountain Valley MD Holdings, Snowline Gold, Altamira Gold Corp, Heritage Cannabis Holdings and Planet 13 Holdings - StreetInsider.com
streetinsider.com - May 5 at 4:44 PM
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial - StreetInsider.comInvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial - StreetInsider.com
streetinsider.com - May 5 at 4:44 PM
Genprex (GNPX) Shares Decline After FDA Board Approves Clinical Trial - InvestorsObserverGenprex (GNPX) Shares Decline After FDA Board Approves Clinical Trial - InvestorsObserver
investorsobserver.com - May 5 at 4:44 PM
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer - Business WireGenprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer - Business Wire
businesswire.com - May 5 at 11:44 AM
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung CancerGenprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
finance.yahoo.com - May 5 at 11:44 AM
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Acclaim-2 Clinical Trial - StreetInsider.comInvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Acclaim-2 Clinical Trial - StreetInsider.com
streetinsider.com - May 4 at 11:57 PM
Proactive news headlines including SIGMA Lithium Resources, Marvel Discovery, Green Battery Minerals and Byrna Technologies - StreetInsider.comProactive news headlines including SIGMA Lithium Resources, Marvel Discovery, Green Battery Minerals and Byrna Technologies - StreetInsider.com
streetinsider.com - May 4 at 6:57 PM
Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer - Business WireGenprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer - Business Wire
businesswire.com - May 4 at 1:57 PM
Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung CancerGenprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
finance.yahoo.com - May 4 at 1:57 PM
Genprex to Participate in CEO Roadshow Webinar Series - Business WireGenprex to Participate in CEO Roadshow Webinar Series - Business Wire
businesswire.com - April 21 at 1:55 PM
Genprex to Participate in CEO Roadshow Webinar SeriesGenprex to Participate in CEO Roadshow Webinar Series
finance.yahoo.com - April 21 at 1:55 PM
Should You Accumulate Genprex Inc (GNPX) in Biotechnology Industry? - InvestorsObserverShould You Accumulate Genprex Inc (GNPX) in Biotechnology Industry? - InvestorsObserver
investorsobserver.com - April 20 at 5:10 PM
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives License of Year Award for Advances Made with Gene Therapy Program in Diabetes - StreetInsider.comBioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives License of Year Award for Advances Made with Gene Therapy Program in Diabetes - StreetInsider.com
streetinsider.com - April 20 at 5:10 PM
Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes - Business WireGenprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes - Business Wire
businesswire.com - April 20 at 5:10 PM
DateCompanyBrokerageAction
11/18/2019Jaguar HealthHC WainwrightReiterated Rating
9/12/2019Jaguar HealthLADENBURG THALM/SH SHInitiated Coverage
5/6/2021ChiasmaJefferies Financial GroupDowngrade
5/5/2021ChiasmaPiper SandlerDowngrade
3/17/2020ChiasmaCantor FitzgeraldReiterated Rating
7/31/2019ChiasmaPiper Jaffray CompaniesInitiated Coverage
7/24/2019ChiasmaBrookline Capital ManagementReiterated Rating
2/19/2019ChiasmaRoth CapitalInitiated Coverage
3/17/2021AVEO PharmaceuticalsSVB LeerinkBoost Price Target
11/9/2020AVEO PharmaceuticalsStifel NicolausInitiated Coverage
5/29/2020AVEO PharmaceuticalsRobert W. BairdBoost Price Target
3/28/2019AVEO PharmaceuticalsNational SecuritiesInitiated Coverage
2/4/2019AVEO PharmaceuticalsB. RileyReiterated Rating
3/29/2019NovanJMP SecuritiesDowngrade
5/26/2020GenprexNoble FinancialReiterated Rating
4/22/2020GenprexAlliance Global PartnersInitiated Coverage
4/1/2019GenprexMaxim GroupDowngrade
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.